01.03.2011 | Research Articles
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2011
Einloggen, um Zugang zu erhalten